{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,16]],"date-time":"2025-09-16T19:19:36Z","timestamp":1758050376821,"version":"3.44.0"},"reference-count":39,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,5,11]],"date-time":"2022-05-11T00:00:00Z","timestamp":1652227200000},"content-version":"am","delay-in-days":375,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bulletin du Cancer"],"published-print":{"date-parts":[[2021,5]]},"DOI":"10.1016\/j.bulcan.2021.01.014","type":"journal-article","created":{"date-parts":[[2021,4,23]],"date-time":"2021-04-23T04:01:31Z","timestamp":1619150491000},"page":"521-527","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Syndrome de Richter\u00a0: prise en charge diagnostique et th\u00e9rapeutique"],"prefix":"10.1016","volume":"108","author":[{"given":"Carolyne","family":"Croizier","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Romain","family":"Gui\u00e8ze","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.bulcan.2021.01.014_bib0200","unstructured":"Richter MN. Generalized reticular cell sarcoma of lymph nodes associated with lymphatic leukemia. American journal of pathology.:15."},{"issue":"6","key":"10.1016\/j.bulcan.2021.01.014_bib0205","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1111\/bjh.12458","article-title":"Diffuse large B-cell lymphoma (Richter syndrome) in patients with chronic lymphocytic leukaemia (CLL): a cohort study of newly diagnosed patients","volume":"162","author":"Parikh","year":"2013","journal-title":"British Journal of Haematology"},{"issue":"21","key":"10.1016\/j.bulcan.2021.01.014_bib0210","doi-asserted-by":"crossref","first-page":"2867","DOI":"10.1182\/blood.V122.21.2867.2867","article-title":"Heritable Predisposition To Richter Syndrome In Patients With Chronic Lymphocytic Leukemia","volume":"122","author":"Parikh","year":"2013","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.bulcan.2021.01.014_bib0215","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1111\/j.1365-2141.2008.07248.x","article-title":"Richter syndrome: a review of clinical, ocular, neurological and other manifestations","volume":"142","author":"Omoti","year":"2008","journal-title":"British Journal of Haematology"},{"issue":"27","key":"10.1016\/j.bulcan.2021.01.014_bib0220","doi-asserted-by":"crossref","first-page":"3059","DOI":"10.1200\/JCO.2013.54.8800","article-title":"Recommendations for Initial Evaluation, Staging, and Response Assessment of Hodgkin and Non-Hodgkin Lymphoma: The Lugano Classification","volume":"32","author":"Cheson","year":"2014","journal-title":"Journal of Clinical Oncology"},{"issue":"6","key":"10.1016\/j.bulcan.2021.01.014_bib0225","doi-asserted-by":"crossref","first-page":"1474","DOI":"10.3109\/10428194.2015.1099643","article-title":"An 18F-FDG-PET maximum standardized uptake value>10\u00a0represents a novel valid marker for discerning Richter's Syndrome","volume":"57","author":"Michallet","year":"2016","journal-title":"Leuk Lymphoma"},{"issue":"11","key":"10.1016\/j.bulcan.2021.01.014_bib0230","doi-asserted-by":"crossref","first-page":"2258","DOI":"10.3324\/haematol.2018.207068","article-title":"Utility of positron emission tomography-computed tomography in patients with chronic lymphocytic leukemia following B-cell receptor pathway inhibitor therapy","volume":"104","author":"Mato","year":"2019","journal-title":"Haematologica"},{"issue":"20","key":"10.1016\/j.bulcan.2021.01.014_bib0235","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1182\/blood-2016-01-643569","article-title":"The 2016\u00a0revision of the World Health Organization classification of lymphoid neoplasms","volume":"127","author":"Swerdlow","year":"2016","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.bulcan.2021.01.014_bib0240","doi-asserted-by":"crossref","first-page":"1620","DOI":"10.3324\/haematol.13881","volume":"95","year":"2010","journal-title":"Haematologica"},{"key":"10.1016\/j.bulcan.2021.01.014_bib0245","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.humpath.2016.04.019","article-title":"Hodgkin lymphoma variant of Richter transformation: morphology, Epstein-Barr virus status, clonality, and survival analysis-with comparison to Hodgkin-like lesion","volume":"55","author":"Xiao","year":"2016","journal-title":"Hum Pathol"},{"issue":"15","key":"10.1016\/j.bulcan.2021.01.014_bib0250","doi-asserted-by":"crossref","first-page":"2673","DOI":"10.1182\/blood-2013-03-489518","article-title":"Two main genetic pathways lead to the transformation of chronic lymphocytic leukemia to Richter syndrome","volume":"122","author":"Chigrinova","year":"2013","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.bulcan.2021.01.014_bib0255","doi-asserted-by":"crossref","first-page":"2273","DOI":"10.1084\/jem.20131448","article-title":"Genetic lesions associated with chronic lymphocytic leukemia transformation to Richter syndrome","volume":"210","author":"Fabbri","year":"2013","journal-title":"J Exp Med"},{"issue":"10","key":"10.1016\/j.bulcan.2021.01.014_bib0260","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1097\/PAS.0b013e31804bdaf8","article-title":"IgVH Mutational Status and Clonality Analysis of Richter's Transformation: Diffuse Large B-cell Lymphoma and Hodgkin Lymphoma in Association With B-cell Chronic Lymphocytic Leukemia (B-CLL) Represent 2\u00a0Different Pathways of Disease Evolution","volume":"31","author":"Mao","year":"2007","journal-title":"The American Journal of Surgical Pathology"},{"issue":"12","key":"10.1016\/j.bulcan.2021.01.014_bib0265","doi-asserted-by":"crossref","first-page":"5646","DOI":"10.1182\/blood-2008-01-129726","article-title":"CD38\u00a0gene polymorphism and chronic lymphocytic leukemia: a role in transformation to Richter syndrome?","volume":"111","author":"Aydin","year":"2008","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.bulcan.2021.01.014_bib0270","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1111\/j.1365-2141.2010.08482.x","article-title":"A variant of the LRP4\u00a0gene affects the risk of chronic lymphocytic leukaemia transformation to Richter syndrome","volume":"152","author":"Rasi","year":"2011","journal-title":"Br J Haematol"},{"issue":"6","key":"10.1016\/j.bulcan.2021.01.014_bib0275","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1038\/leu.2008.399","article-title":"Telomere length is an independent predictor of survival, treatment requirement and Richter's syndrome transformation in chronic lymphocytic leukemia","volume":"23","author":"Rossi","year":"2009","journal-title":"Leukemia"},{"issue":"12","key":"10.1016\/j.bulcan.2021.01.014_bib0280","doi-asserted-by":"crossref","first-page":"3391","DOI":"10.1182\/blood-2010-09-302174","article-title":"The genetics of Richter syndrome reveals disease heterogeneity and predicts survival after transformation","volume":"117","author":"Rossi","year":"2011","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.bulcan.2021.01.014_bib0285","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s00277-017-3149-9","article-title":"Approach to Richter transformation of chronic lymphocytic leukemia in the era of novel therapies","volume":"97","author":"Khan","year":"2018","journal-title":"Ann Hematol"},{"issue":"15","key":"10.1016\/j.bulcan.2021.01.014_bib0290","doi-asserted-by":"crossref","first-page":"2343","DOI":"10.1200\/JCO.2005.05.0187","article-title":"Clinical Outcomes and Prognostic Factors in Patients With Richter's Syndrome Treated With Chemotherapy or Chemoimmunotherapy With or Without Stem-Cell Transplantation","volume":"24","author":"Tsimberidou","year":"2006","journal-title":"Journal of Clinical Oncology"},{"issue":"2","key":"10.1016\/j.bulcan.2021.01.014_bib0295","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1111\/j.1365-2141.2008.07166.x","article-title":"Biological and clinical risk factors of chronic lymphocytic leukaemia transformation to Richter syndrome","volume":"142","author":"Rossi","year":"2008","journal-title":"Br J Haematol"},{"issue":"12","key":"10.1016\/j.bulcan.2021.01.014_bib0300","doi-asserted-by":"crossref","first-page":"E239","DOI":"10.1002\/ajh.23841","article-title":"Poor efficacy and tolerability of R-CHOP in relapsed\/refractory chronic lymphocytic leukemia and Richter transformation","volume":"89","author":"Langerbeins","year":"2014","journal-title":"Am J Hematol"},{"issue":"1","key":"10.1016\/j.bulcan.2021.01.014_bib0305","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1111\/bjh.14177","article-title":"NCRI phase II study of CHOP in combination with ofatumumab in induction and maintenance in newly diagnosed Richter syndrome","volume":"175","author":"Eyre","year":"2016","journal-title":"British Journal of Haematology"},{"issue":"5","key":"10.1016\/j.bulcan.2021.01.014_bib0310","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1016\/j.clml.2013.03.012","article-title":"Phase I-II clinical trial of oxaliplatin, fludarabine, cytarabine, and rituximab therapy in aggressive relapsed\/refractory chronic lymphocytic leukemia or Richter syndrome","volume":"13","author":"Tsimberidou","year":"2013","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"2","key":"10.1016\/j.bulcan.2021.01.014_bib0315","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1200\/JCO.2007.11.8513","article-title":"Phase I-II study of oxaliplatin, fludarabine, cytarabine, and rituximab combination therapy in patients with Richter's syndrome or fludarabine-refractory chronic lymphocytic leukemia","volume":"26","author":"Tsimberidou","year":"2008","journal-title":"J Clin Oncol"},{"issue":"7","key":"10.1016\/j.bulcan.2021.01.014_bib0320","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1002\/cncr.11238","volume":"97","author":"Tsimberidou","year":"2003","journal-title":"Cancer"},{"issue":"4","key":"10.1016\/j.bulcan.2021.01.014_bib0325","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1080\/10428190290016872","article-title":"Phase II study of fludarabine, cytarabine (Ara-C), cyclophosphamide, cisplatin and GM-CSF (FACPGM) in patients with Richter's syndrome or refractory lymphoproliferative disorders","volume":"43","author":"Tsimberidou","year":"2002","journal-title":"Leuk Lymphoma"},{"issue":"3","key":"10.1016\/j.bulcan.2021.01.014_bib0330","doi-asserted-by":"crossref","first-page":"329","DOI":"10.3109\/10428190109064589","article-title":"Fractionated cyclophosphamide, vincristine, liposomal daunorubicin (daunoXome), and dexamethasone (hyperCVXD) regimen in Richter's syndrome","volume":"42","author":"Dabaja","year":"2001","journal-title":"Leuk Lymphoma"},{"issue":"2","key":"10.1016\/j.bulcan.2021.01.014_bib0335","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1111\/bjh.15035","article-title":"A single-institution retrospective cohort study of first-line R-EPOCH chemoimmunotherapy for Richter syndrome demonstrating complex chronic lymphocytic leukaemia karyotype as an adverse prognostic factor","volume":"180","author":"Rogers","year":"2018","journal-title":"Br J Haematol"},{"issue":"2","key":"10.1016\/j.bulcan.2021.01.014_bib0340","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1111\/ejh.12474","article-title":"Platinum and high-dose cytarabine-based regimens are efficient in ultra high\/high-risk chronic lymphocytic leukemia and Richter's syndrome: results of a French retrospective multicenter study","volume":"95","author":"Durot","year":"2015","journal-title":"Eur J Haematol"},{"issue":"24","key":"10.1016\/j.bulcan.2021.01.014_bib0345","doi-asserted-by":"crossref","first-page":"3175","DOI":"10.1182\/blood-2016-11-750174","article-title":"Selective inhibition of nuclear export with selinexor in patients with non-Hodgkin lymphoma","volume":"129","author":"Kuruvilla","year":"2017","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.bulcan.2021.01.014_bib0350","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1200\/JCO.2016.70.4320","article-title":"Phase I First-in-Human Study of Venetoclax in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma","volume":"35","author":"Davids","year":"2017","journal-title":"J Clin Oncol"},{"issue":"10","key":"10.1016\/j.bulcan.2021.01.014_bib0355","doi-asserted-by":"crossref","first-page":"1676","DOI":"10.1182\/blood-2014-12-610782","article-title":"The efficacy of ibrutinib in the treatment of Richter syndrome","volume":"125","author":"Tsang","year":"2015","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.bulcan.2021.01.014_bib0360","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1186\/s12885-019-5717-y","volume":"19","author":"Appleby","year":"2019","journal-title":"BMC Cancer"},{"issue":"18","key":"10.1016\/j.bulcan.2021.01.014_bib0365","doi-asserted-by":"crossref","first-page":"2211","DOI":"10.1200\/JCO.2011.37.4108","volume":"30","author":"Cwynarski","year":"2012","journal-title":"J Clin Oncol"},{"issue":"26","key":"10.1016\/j.bulcan.2021.01.014_bib0370","doi-asserted-by":"crossref","first-page":"3010","DOI":"10.1200\/JCO.2017.72.8519","article-title":"Durable Molecular Remissions in Chronic Lymphocytic Leukemia Treated With CD19-Specific Chimeric Antigen Receptor-Modified T Cells After Failure of Ibrutinib","volume":"35","author":"Turtle","year":"2017","journal-title":"J Clin Oncol"},{"issue":"26","key":"10.1016\/j.bulcan.2021.01.014_bib0375","doi-asserted-by":"crossref","first-page":"3419","DOI":"10.1182\/blood-2017-02-765685","article-title":"Pembrolizumab in patients with CLL and Richter transformation or with relapsed CLL","volume":"129","author":"Ding","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.bulcan.2021.01.014_bib0380","doi-asserted-by":"crossref","unstructured":"Armand P, Murawski N, Molin D, Zain J, Eichhorst B, Gulbas Z, et al. Pembrolizumab in relapsed or refractory Richter syndrome. British Journal of Haematology [Internet]. [cited 2020\u00a0Jun 18];n\/a(n\/a). Available from: https:\/\/onlinelibrary.wiley.com\/doi\/abs\/10.1111\/bjh.16762.","DOI":"10.1111\/bjh.16762"},{"issue":"1","key":"10.1016\/j.bulcan.2021.01.014_bib0385","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1182\/blood-2017-07-740993","article-title":"PD-1\u00a0expression and clinical PD-1\u00a0blockade in B-cell lymphomas","volume":"131","author":"Xu-Monette","year":"2018","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.bulcan.2021.01.014_bib0195","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1002\/ajh.24714","article-title":"Factors predicting survival in chronic lymphocytic leukemia patients developing Richter syndrome transformation into Hodgkin lymphoma","volume":"92","author":"Mauro","year":"2017","journal-title":"Am J Hematol"}],"container-title":["Bulletin du Cancer"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S000745512100120X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S000745512100120X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,13]],"date-time":"2025-09-13T19:34:06Z","timestamp":1757792046000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S000745512100120X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5]]},"references-count":39,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2021,5]]}},"alternative-id":["S000745512100120X"],"URL":"https:\/\/doi.org\/10.1016\/j.bulcan.2021.01.014","relation":{},"ISSN":["0007-4551"],"issn-type":[{"type":"print","value":"0007-4551"}],"subject":[],"published":{"date-parts":[[2021,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Syndrome de Richter\u00a0: prise en charge diagnostique et th\u00e9rapeutique","name":"articletitle","label":"Article Title"},{"value":"Bulletin du Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bulcan.2021.01.014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Soci\u00e9t\u00e9 Fran\u00e7aise du Cancer. Published by Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}